[Cellular immunity in melanomalignome (author's transl)].
Cellular immunological reactivity was examined in 20 patients having melanomalignoma at different clinical stages, using Leukocyte-Migration-Inhibition-Test. As antigens three homologous melanoma-extracts were used, produced by our own method. Independent from the clinical stages cell-migration inhibition could be established in 15 out of the 20 patients. In this way, these tumor extracts have been shown to contain melanoma-associated antigens. Regardless of the clinical stage of the disease, the melanomalignomas patient produces cellular immunity against those tumor-antigens. It is note-worthy that the actual course of the disease seems not to be influenced by immun-mechanisms.
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis; D002464:Cell Migration Inhibition; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007962:Leukocytes / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000276:immunology*; D008875:Middle Aged; D009508:Nevus, Pigmented / Q000276:immunology; D012878:Skin Neoplasms / Q000276:immunology*; D013577:Syndrome; D014820:Vitiligo / Q000276:immunology
D000951:Antigens, Neoplasm
Zur celluären Immunität beim Melanomalignom